Combination of oxidative stress and steatosis is a risk factor for fibrosis in alcohol-drinking patients with chronic hepatitis C

American Journal of Gastroenterology

Volumn 103, Issue 1, 2008, Pages 147-153

  Vidali, Matteo ^a   Occhino, Giuseppa ^a   Ivaldi, Alessandra ^a   Rigamonti, Cristina ^a,c   Sartori, Massimo ^b   Albano, Emanuele ^a  

^a UNIVERSITY OF EASTERN PIEDMONT   (Italy)

^b MAGGIORE DELLA CARITÀ HOSPITAL   (Italy)

^c FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; FERRITIN; IMMUNOGLOBULIN; IMMUNOGLOBULIN G; IRON; LIVER ENZYME; TRANSFERRIN;

ADULT; AGE; AGED; ALCOHOL CONSUMPTION; ARTICLE; BODY MASS; CHRONIC HEPATITIS; DATA ANALYSIS; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FATTY LIVER; FEMALE; HEPATITIS C; HEPATITIS C VIRUS; HISTOPATHOLOGY; HUMAN; IMMUNE RESPONSE; IRON STORAGE; LIPID PEROXIDATION; LIVER FIBROSIS; LIVER FUNCTION TEST; LIVER NECROSIS; MAJOR CLINICAL STUDY; MALE; OXIDATIVE STRESS; PRIORITY JOURNAL; RISK FACTOR; STATISTICAL ANALYSIS;

ADULT; AGED; ALCOHOL DRINKING; ANTIBODIES, ANTI-IDIOTYPIC; BIOPSY; DISEASE PROGRESSION; FATTY LIVER; FEMALE; HEPATITIS C, CHRONIC; HUMANS; IMMUNOGLOBULIN G; LIPID PEROXIDATION; LIVER CIRRHOSIS; MALE; MIDDLE AGED; OXIDATIVE STRESS; PROGNOSIS; RISK FACTORS;

EID: 37849038662     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1111/j.1572-0241.2007.01596.x     Document Type: Article

References (40)

1. Feld JJ, Liang TJ. Hepatitis C: Identifying patients with progressive liver injury. Hepatol 2006 43 : S194 206.
2. Massard J, Ratziu V, Thabut D, et al. Natural history and predictors of disease severity in chronic hepatitis C. J Hepatol 2006 44 : S19 24.
3. Vento S, Cainelli F. Does hepatitis C virus cause severe liver disease only in people who drink alcohol? Lancet Inf Dis 2002 2 : 303 9.
4. Peters MG, Terrault NA. Alcohol use and hepatitis C. Hepatol 2002 36 : S220 5.
5. Corrao G, Aricò S. Independent and combined action of hepatitis C virus infection and alcohol consumption on the risk of symptomatic liver cirrhosis. Hepatol 1998 27 : 914 9.
6. Westin J, Lagging LM, Spak F, et al. Moderate alcohol intake increases fibrosis progression in untreated patients with hepatitis C virus infection. J Vir Hepat 2002 9 : 235 41.
7. Arteel GE. Oxidant and antioxidant in alcohol-induced liver disease. Gastroenterology 2003 124 : 778 90.
8. Albano E. Alcohol, oxidative stress, and free radicals. Proc Nutr Soc 2006 65 : 278 90.
9. Choi J, Ou JHJ. Mechanisms of liver injury III : Oxidative stress in the pathogenesis of hepatitis C virus. Am J Physiol 2006 290 : G847 51.
10. Farinati F, Cardin R, De Maria N, et al. Iron storage, lipid peroxidation, and glutathione turnover in chronic anti-HCV positive hepatitis. J. Hepatology 1995 22 : 449 56.
11. Jain SK, Pemberton PW, Smith A, et al. Oxidative stress in chronic hepatitis C: Not just a feature of late-stage disease. J Hepatology 2002 36 : 805 11.
12. Paradis V, Mathurin P, Kolliger M, et al. In situ detection of lipid peroxidation in chronic hepatitis C: Correlation with pathological features. J Clin Pathology 1997 50 : 401 6.
13. Vendemiale G, Grattagliano I, Portincasa P, et al. Oxidative stress in symptom-free HCV carriers: Relation with ALT flare-up. Eur J Clin Invest 2001 31 : 54 63.
14. Gong G, Waris G, Tanveer R, et al. Human hepatitis C virus NS5A protein alters intracellular calcium levels, induces oxidative stress, and activates STAT-3 and NF-kappa B. Proc Natl Acad Sci U S A 2001 98 : 9599 604.
15. Okuda M, Li K, Beard MR, et al. Mitochondrial injury, oxidative stress, and antioxidant gene expression are induced by hepatitis C virus core protein. Gastroenterology 2002 122 : 366 75.
16. Korenaga M, Wang T, Li Y, et al. Hepatitis C virus core protein inhibits mitochondrial electron transport and increases reactive oxygen species (ROS) production. J Biol Chem 2005 280 : 37481 8.
17. Moriya K, Nakagawa K, Santa T, et al. Oxidative stress in the absence of inflammation in a mouse model for hepatitis C virus-associated hepatocarcinogenesis. Cancer Res 2001 61 : 4365 70.
18. Perlemutter G, Letteron P, Carnot F, et al. Alcohol and hepatitis C core protein additively increase lipid peroxidation and synergically trigger hepatic cytokine expression in a transgenic mouse model. J Hepatology 2003 39 : 1020 7.
19. Otani K, Korenaga M, Beard MR, et al. Hepatitis C core protein, cytochrome P4502E1, and alcohol produce combined mitochrondrial injury and cytotoxicity in hepatoma cells. Gastroenterology 2005 128 : 96 107.
20. Rigamonti C, Mottaran E, Reale E, et al. Moderate alcohol consumption increases oxidative stress in patients with chronic hepatitis C. Hepatology 2003 38 : 42 9.
21. Albano E, Mottaran E, Vidali M, et al. Immune response toward lipid peroxidation products as a predictor of the progression of non-alcoholic fatty liver disease (NAFLD) to advanced fibrosis. Gut 2005 54 : 987 93.
22. Corrao G, Arico S, Lepore R, et al. Amount and duration of alcohol intake as risk factors of symptomatic liver cirrhosis: A case-control study. J Clin Epidemiol 1993 46 : 601 7.
23. Ishak K, Baptista A, Bianchi L, et al. Histological grading and staging of chronic hepatitis. J Hepatology 1995 22 : 696 9.
24. Adinolfi LE, Gambarella M, Andreana A, et al. Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity. Hepatology 2001 33 : 1358 64.
25. Serfaty L, Poujol-Robert, Carbonell N, et al. Effect of the interaction between steatosis and alcohol intake on liver fibrosis progression in chronic hepatitis C. Am J Gastroenterology 2002 97 : 1807 12.
26. Fartoux L, Poujol-Robert A, Guéchot J, et al. Insulin resistance is a cause of steatosis and fibrosis progression in chronic hepatitis C. Gut 2005 54 : 1003 8.
27. Leandro G, Mangia A, Hui J, et al. HCV meta-analysis (on) individual patients' data study group. Relationship between steatosis, inflammation, and fibrosis in chronic hepatitis C: A meta-analysis of individual patient data. Gastroenterology 2006 130 : 1636 42.
28. Lonardo A, Adinolfi LE, Loria P, et al. Steatosis and hepatitis C virus: Mechanisms and significance for hepatic and extrahepatic disease. Gastroenterology 2004 126 : 586 97.
29. Asselah T, Rubbia-Brandt L, Marcelllin P, et al. Steatosis in chronic hepatitis C: Why does it really matter? Gut 2006 55 : 123 30.
30. Berson A, De Beco V, Letteron P, et al. Steatohepatitis-inducing drugs cause mitochondrial dysfunction and lipid peroxidation in rat hepatocytes. Gastroenterology 1998 114 : 764 74.
31. Alla V, Bonkovsky HL. Iron in nonhemochromatotic liver disorders. Semin Liver Dis 2005 25 : 461 72.
32. Schaffler A, Scholmerich J, Buchler C. Mechanisms of disease: Adipocytokines and visceral adipose tissue - emerging role in non-alcoholic fatty liver disease. Nat Clin Pract Gastroenterol Hepatol. 2005 2 : 273 80.
33. Day CP. From fat to inflammation. Gastroenterology 2006 130 : 207 10.
34. Charlton MR, Pockros PJ, Harrison SA. Impact of obesity on treatment of chronic hepatitis C. Hepatology 2006 43 : 1177 86.
35. Nieto N, Rojkind M. Repeated whiskey binges promote liver injury in rats fed on a choline-deficient diet. J Hepatol 2007 46 : 330 9.
36. Safadi R, Ohta M, Alvarez CE, et al. Immune stimulation of hepatic fibrogenesis by CD8 cells and attenuation by transgenic interleukin-10 from hepatocytes. Gastroenterology 2004 127 : 870 82.
37. Li Z, Soloski MJ, Diehl AM. Dietary factors alter hepatic innate immune system in mice with non-alcoholic fatty liver disease. Hepatology 2005 42 : 880 5.
38. Kremer M, Hines IN, Milton RJ, et al. Favored T helper 1 response in a mouse model of hepatosteatosis is associated with enhanced T cell-mediated hepatitis. Hepatology 2006 44 : 216 27.
39. Tilg H, Moschen AR. Adipokines: Mediators linking adipose tissue, inflammation, and immunity. Nat Rev Immunol 2006 6772 83.
40. Melhem A, Stern M, Shibolet O, et al. Treatment of chronic hepatitis C virus infection via antioxidants: Results of a phase I clinical trial. J Clin Gastroenterol 2005 39 : 737 42.